{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"77","upperLimit":"95","value":"89"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"}],"units":"Participants"}],"description":"Percentage of patients who did not die by the disease within 4 years","dispersionType":"95% Confidence Interval","groups":[{"description":"Single arm, two-stage, phase II trial of induction therapy with carboplatin and paclitaxel, followed by ZD1839, 5-FU, hydroxyurea, and hyperfractionated radiotherapy, followed by adjuvant ZD1839 alone.\n\nInduction chemotherapy: ZD 1839 (250mg/day), two cycles of Paclitaxel (100mg/m2 days 1, 8, 15), Carboplatin (AUC 6, day 1). Concurrent chemotherapy and radiation treatment began 1-2 weeks after induction chemotherapy: 4-5 14 day cycles (5 days of 500 mg of hydroxyurea orally every 12 h, 600mg/m2/d of continuous infusion fluorouracil, and 1.5Gy of radiation twice per day followed by 9 days without therapy.","id":"OG000","title":"ZD1839 500mg by Mouth (po) Daily"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"0.3 to 4.7 years","title":"4 Year Disease Specific Survival","type":"SECONDARY","unitOfMeasure":"percentage of patients"}